173 related articles for article (PubMed ID: 22931650)
41. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
42. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Yao Y; Zhou J; Wang L; Gao X; Ning Q; Jiang M; Wang J; Wang L; Yu L
PLoS One; 2013; 8(8):e70522. PubMed ID: 23940586
[TBL] [Abstract][Full Text] [Related]
43. [Regulatory effect of curcumin on p300 and HDAC1 in B-NHL cells].
Wu Q; Chen Y; Li XG; Tang YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):293-7. PubMed ID: 16638200
[TBL] [Abstract][Full Text] [Related]
44. [ITF-2357 on inhibition myeloid leukemic cell lines cells proliferation in vitro and its mechanism].
Yu WJ; Wang L; You LS; Mei C; Ma QL; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):366-70. PubMed ID: 22781793
[TBL] [Abstract][Full Text] [Related]
45. Chidamide induces necroptosis via regulation of c‑FLIPL expression in Jurkat and HUT‑78 cells.
Chi Z; Gao H; Liu H; Wu B; Zhang B; Gu M; Yang W
Mol Med Rep; 2020 Feb; 21(2):936-944. PubMed ID: 31974619
[TBL] [Abstract][Full Text] [Related]
46. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV-infected patients on suppressive antiretroviral therapy.
Li JH; Ma J; Kang W; Wang CF; Bai F; Zhao K; Yao N; Liu Q; Dang BL; Wang BW; Wei QQ; Kang WZ; Sun YT
HIV Med; 2020 Dec; 21(11):747-757. PubMed ID: 33369029
[TBL] [Abstract][Full Text] [Related]
47. Antitumor activity of Chidamide in hepatocellular carcinoma cell lines.
Wang H; Guo Y; Fu M; Liang X; Zhang X; Wang R; Lin C; Qian H
Mol Med Rep; 2012 Jun; 5(6):1503-8. PubMed ID: 22484326
[TBL] [Abstract][Full Text] [Related]
48. Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation.
He M; Qiao Z; Wang Y; Kuai Q; Li C; Wang Y; Jiang X; Wang X; Li W; He M; Ren S; Yu Q
PLoS One; 2016; 11(11):e0166896. PubMed ID: 27875574
[TBL] [Abstract][Full Text] [Related]
49. Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo.
Liu X; Li W; Xu L; Chen X; Zhao R; Guo Y; Ge J; Yang Z; Li L; Zhang J; Cao J; Shao Y; Guo X; Tian L; Liu M
Int J Biochem Cell Biol; 2023 May; 158():106398. PubMed ID: 36933859
[TBL] [Abstract][Full Text] [Related]
50. Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy.
Gao S; Li X; Zang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2017; 17(6):802-812. PubMed ID: 27592546
[TBL] [Abstract][Full Text] [Related]
51. [Effect of curcumin on acetylation of histone H3 in human lymphoma cell line Raji].
Li XG; Chen Y; Wu Q; Sun CY
Ai Zheng; 2006 May; 25(5):582-6. PubMed ID: 16687078
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
53. Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.
Shi P; Zhang L; Chen K; Jiang Z; Deng M; Zha J; Guo X; Li P; Xu B
Pharmacogenomics; 2017 Aug; 18(13):1259-1270. PubMed ID: 28745928
[TBL] [Abstract][Full Text] [Related]
54. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Dong M; Ning ZQ; Xing PY; Xu JL; Cao HX; Dou GF; Meng ZY; Shi YK; Lu XP; Feng FY
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1413-22. PubMed ID: 22362161
[TBL] [Abstract][Full Text] [Related]
55. Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib.
Xu L; Feng J; Tang H; Dong Y; Shu M; Chen X
Cell Death Dis; 2020 Apr; 11(4):297. PubMed ID: 32341332
[TBL] [Abstract][Full Text] [Related]
56. Chidamide tablets: HDAC inhibition to treat lymphoma.
Xu Y; Zhang P; Liu Y
Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
[TBL] [Abstract][Full Text] [Related]
57. (-)-Epigallocatechingallate induces apoptosis in B lymphoma cells via caspase-dependent pathway and Bcl-2 family protein modulation.
Wang J; Xie Y; Feng Y; Zhang L; Huang X; Shen X; Luo X
Int J Oncol; 2015 Apr; 46(4):1507-15. PubMed ID: 25647297
[TBL] [Abstract][Full Text] [Related]
58. Anticancer activities of trichostatin A on maligant lymphoid cells.
Sun C; Liu X; Chen Y; Liu F
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):538-41. PubMed ID: 17219961
[TBL] [Abstract][Full Text] [Related]
59. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
60. Autophagic Vacuole Secretion Triggered by Chidamide Participates in TRAIL Apoptosis Effect in Breast Cancer Cells.
Zhou W; Han H; Xu J; Sun T; Feng X
Curr Pharm Des; 2021; 27(20):2366-2380. PubMed ID: 32787747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
